FarmaKology-New trial to allow pharmacists to prescribe medication
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to?“[email protected] ”, and happy to have you featured on our newsletter?(+16K Subscribers)!
Today's Company
Terremoto Biosciences ?is a covalent drug discovery and development engine creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy. The company leverages the power of lysine-based covalency across the disease spectrum to develop both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Many of Terremoto’s founders helped establish this emergent area of science, with the intent to broaden the number of tractable targets and deliver medicines with superior therapeutic benefit. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.
News
Ionis Pharmaceuticals, Inc. ?and?Metagenomi? today announced that the companies have entered a collaboration that will leverage?Ionis ’ extensive expertise in RNA-targeted therapeutics and?Metagenomi ’s versatile next-generation gene editing systems to pursue a mix of validated and novel genetic targets that have potential to expand therapeutic options for patients. The companies will jointly conduct research aimed initially at delivering investigational medicines for up to four genetic targets. Ionis has the right to add four more targets upon achievement of pre-determined development milestones.
HitGen Inc. ?today announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd, a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients’ lives.?HitGen? will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
EpiEndo Pharmaceuticals , the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients. EP395 is an orally available macrolide or ‘Barriolide?,’ with reduced antimicrobial resistance potential, which aims to address the unmet medical need for a treatment for COPD.
?ImmunoGen Inc.,? a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the?US Food and Drug Administration (FDA) ?has granted accelerated approval for ELAHERE? (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
?Exscientia plc ?and?The University of Texas MD Anderson Cancer Center ?today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of?Exscientia? with the drug discovery and development expertise of?MD Anderson ?in order to advance novel small-molecule oncology therapies.